Skip to main content
Fig. 3 | BMC Ophthalmology

Fig. 3

From: Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW

Fig. 3

Mean BCVA score at baseline and at Month 24. FAS targeted: n = 264. Regular treatment interval cohort: n = 70. Irregular treatment interval cohort with initial doses: n = 142. Irregular treatment interval cohort without initial doses: n = 40. BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, FAS full analysis set

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us